Literature DB >> 1683566

Involvement of the RAF1 locus, at band 3p25, in the 3p deletion of small-cell lung cancer.

S L Graziano1, A M Pfeifer, J R Testa, G E Mark, B E Johnson, E J Hallinan, O S Pettengill, G D Sorenson, A H Tatum, H Brauch.   

Abstract

The ability to establish long-term cell lines of small-cell lung cancer (SCLC) has provided an in vitro model for the disease. We report on the characterization of 10 new human SCLC cell lines established from 34 cytopathologically positive specimens. Based on morphologic and biochemical characterization, growth properties, and expression of MYC and neuroendocrine properties, eight cell lines were categorized as "classic" and two cell lines as "variant". Cytogenetic examination revealed loss of all or part of 3p in all nine SCLC cell lines analyzed. The smallest deletion in common was found at 3p21-3p25. Restriction fragment length polymorphism (RFLP) analyses with probes for 3p were performed for correlation with karyotypic data and supported the cytogenetic findings. In 21 SCLC specimens (cell lines and tumor tissue) with normal DNA, used for comparison, we observed loss of heterozygosity at RAF1 (3p25) in ten of ten informative pairs by using two RFLPs from the RAF1 locus. In addition, loss of heterozygosity was noted in nine of 10 pairs examined with DNF15S2 (3p21) and four of four with D3S3 (3p14). Analysis of cell lines and tumor specimens that lacked paired normal tissue showed a homozygous pattern with the RAF1 probes in all 18 cases. Northern blots revealed significant expression of RAF1 in all cell lines tested. The transcript size was normal. The cytogenetic and RFLP data suggest that the RAF1 locus at 3p25 is involved in the chromosomal deletion of SCLC.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1683566     DOI: 10.1002/gcc.2870030407

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  6 in total

Review 1.  Selective Raf inhibition in cancer therapy.

Authors:  Vladimir Khazak; Igor Astsaturov; Ilya G Serebriiskii; Erica A Golemis
Journal:  Expert Opin Ther Targets       Date:  2007-12       Impact factor: 6.902

2.  Chemoproteomic Discovery of a Ritanserin-Targeted Kinase Network Mediating Apoptotic Cell Death of Lung Tumor Cells.

Authors:  Sean T Campbell; Caroline E Franks; Adam L Borne; Myungsun Shin; Liuzhi Zhang; Ku-Lung Hsu
Journal:  Mol Pharmacol       Date:  2018-08-29       Impact factor: 4.436

Review 3.  Is the Canonical RAF/MEK/ERK Signaling Pathway a Therapeutic Target in SCLC?

Authors:  Sandra Cristea; Julien Sage
Journal:  J Thorac Oncol       Date:  2016-04-29       Impact factor: 15.609

4.  Enhancement of drug sensitivity of human malignancies by epidermal growth factor.

Authors:  R Kröning; J A Jones; D K Hom; C C Chuang; R Sanga; G Los; S B Howell; R D Christen
Journal:  Br J Cancer       Date:  1995-09       Impact factor: 7.640

5.  An integrative CGH, MSI and candidate genes methylation analysis of colorectal tumors.

Authors:  Hassan Brim; Mones S Abu-Asab; Mehdi Nouraie; Jose Salazar; Jim Deleo; Hadi Razjouyan; Pooneh Mokarram; Alejandro A Schaffer; Fakhraddin Naghibhossaini; Hassan Ashktorab
Journal:  PLoS One       Date:  2014-01-27       Impact factor: 3.240

6.  Silencing of ARL14 Gene Induces Lung Adenocarcinoma Cells to a Dormant State.

Authors:  Fei Guo; Dexiao Yuan; Junling Zhang; Hang Zhang; Chen Wang; Lin Zhu; Jianghong Zhang; Yan Pan; Chunlin Shao
Journal:  Front Cell Dev Biol       Date:  2019-10-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.